Quick Links: Skip to main page content
Skip to Search
Skip to Topics Menu
Skip to Common Links
U.S. Food & Drug Administration
Follow FDA
En Español
Search FDA
Home
Food
Drugs
Medical Devices
Radiation-Emitting Products
Vaccines, Blood & Biologics
Animal & Veterinary
Cosmetics
Tobacco Products
New Pediatric Labeling Information Database - Detail
FDA Home
Pediatrics
New Pediatric Labeling Information Database
Detail
-
Please note:
JavaScript must be enabled for this application to work properly.
Check your settings
if you are unsure if your JavaScript is enabled.
Pediatric Labeling Date:
09/12/2018
Trade Name:
Botox
Generic Name or Proper Name (*):
onabotulinumtoxinA
Indications Studied:
Prevention of headaches in adolescents with chronic migraine
Label Changes Summary:
*Safety and effectiveness in patients below the age of 18 years have not been established. *In a 12-week, multicenter, double-blind, placebo-controlled clinical trial, 123 adolescent patients (ages 12 to below 18 years) with chronic migraine were randomized to receive Botox 74 Units, Botox 155 Units, or placebo, for one injection cycle. This trial did not establish the efficacy of Botox, compared with placebo, for the prophylaxis of headaches in adolescents with chronic migraine. *Postmarketing study.
PREA(P):
P
Sponsor:
Allergan, Inc.
NNPS:
FALSE
Therapeutic Category:
Antimigraine
-
-